

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Lenalidomide in combination with dexamethasone for previously untreated multiple myeloma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

A potential equality issue was identified during the draft scope consultation:

- Access to treatment: people with multiple myeloma attend specialist treatment units for injectable treatment. These patients are often less mobile or live a long distance from their treatment centre meaning they are less likely to receive these treatments.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The benefits of different mode of administration will be taken into account in the appraisal.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not applicable.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
No.

Approved by Associate Director (name): Elisabeth George

Date: 22/08/2017